Nordic Life Science 1
CALENDAR NOVEMBER 19-20 HELSINKI Y Science NOVEMB
ER 25 OSLO DNB Nordic Healthcare Conference JANUARY 12-15 SAN FRANCISCO JPM Healthcare Conference MARCH 23-25 LISBON BIO-Europe Spring MARCH 25-26 NEW YORK Nordic American Healthcare Conference APRIL 15-16 STOCKHOLM LabDays JANUARY 12-15, 2026: JPM HEALTHCARE CONFERENCE MARCH 23-25, 2026: BIO-EUROPE SPRING Jamie Dimon, CEO, JPMorgan, will speak about the future of healthcare investment in his opening keynote. Kate Ryder, founder and CEO of Maven, will speak during a session about investing in women’s healthcare. A European Springtime Partnering Event This event is a key meeting point that connects Europe’s leading innovation hubs with the global life sciences industry, aiming to foster strategic and long-lasting partnerships. JPMHEALTHCONFERENCES.COM BIO-EUROPE SPRING attracts a wide THE WORLD’S LARGEST HEALTHCARE INVESTMENT CONFERENCE The conference, celebrating 44 years 2026, connects global industry leaders, emerging companies, innovative technology creators, and members of the investment community. P REVIOUS EVENTS have had over 8,000 professionals, including executives, investors, and policymakers participating, which is, as always, held at the The Westin St. Francis Hotel in San Francisco, USA. Key themes and insights include Mergers & Acquisitions (major companies are using the conference as a platform to announce acquisitions and partnerships), Innovation and Research (discussions center around emerging technologies and cuttingedge therapies), and Cautious Optimism (while 98 | NORDICLIFESCIENCE.ORG there is enthusiasm for innovation, policy and market challenges temper the overall sentiment). The 2026 event will also have a big focus on AI and include sessions about AI in drug discovery and development, AI in diagnostics, AI for operational efficiency, AI in remote and virtual healthcare, AI and regulatory compliance, and AI ethics and data privacy. Keynote discussions and panels will also focus on ”The future of AI in precision medicine”, ”Ethical AI in healthcare”, and ”Investing in AI for Healthcare”. NLS range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts. The last event, arranged in Milan, Italy, had 18,471 one-to-one meetings, 3,205 delegates from 55 countries, 125 exhibiting companies, 68 onsite presentations & 6 digital presentations, and 24 panels and fireside chats. NLS Lisbon INFORMACONNECT.COM/ BIOEUROPE-SPRING